TSX:IN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has InMed Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.6%

IN

6.7%

CA Biotechs

0.6%

CA Market


1 Year Return

-52.3%

IN

70.4%

CA Biotechs

-7.5%

CA Market

Return vs Industry: IN underperformed the Canadian Biotechs industry which returned 70.4% over the past year.

Return vs Market: IN underperformed the Canadian Market which returned -7.5% over the past year.


Shareholder returns

INIndustryMarket
7 Day0.6%6.7%0.6%
30 Day-19.7%15.0%-1.1%
90 Day-47.2%2.8%6.6%
1 Year-52.3%-52.3%70.4%70.4%-4.2%-7.5%
3 Year-65.6%-65.6%45.5%45.5%10.0%-0.6%
5 Yearn/a-10.2%-10.2%42.3%20.3%

Price Volatility Vs. Market

How volatile is InMed Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InMed Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IN is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: IN is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IN is good value based on its PB Ratio (3.3x) compared to the CA Biotechs industry average (5.8x).


Next Steps

Future Growth

How is InMed Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-3.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IN's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if IN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IN's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has InMed Pharmaceuticals performed over the past 5 years?

-33.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IN is currently unprofitable.

Growing Profit Margin: IN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IN is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.

Accelerating Growth: Unable to compare IN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: IN has a negative Return on Equity (-155.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is InMed Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: IN's short term assets (CA$8.6M) exceed its short term liabilities (CA$2.3M).

Long Term Liabilities: IN's short term assets (CA$8.6M) exceed its long term liabilities (CA$338.0K).


Debt to Equity History and Analysis

Debt Level: IN is debt free.

Reducing Debt: IN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 41% each year


Next Steps

Dividend

What is InMed Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Eric Adams (56 yo)

4.25yrs

Tenure

CA$1,102,598

Compensation

Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences ...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD1.44M) is above average for companies of similar size in the Canadian market ($USD178.23K).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Eric Adams
President4.25yrsCA$1.10m0.59%
CA$ 151.4k
Eric Hsu
Senior Vice President of Preclinical Research & Development2.5yrsCA$556.69k0.024%
CA$ 6.2k
Michael Woudenberg
Vice President of Chemistry1.83yrsCA$263.18k0.010%
CA$ 2.6k
Sazzad Hossain
Co-Founderno dataCA$184.70kno data
Bruce Colwill
CFO & Corporate Secretary1.08yrsno data0.029%
CA$ 7.4k
Brendan Payne
Director of Investor Relationsno datano datano data
Richard Hoy
Vice President of Sales & Marketing16yrsno datano data
Alexandra D. Mancini
Senior Vice President of Clinical & Regulatory Affairs3.92yrsCA$692.50k0.12%
CA$ 29.6k
Ado Muhammad
Senior Consultant of Medical Affairsno datano datano data

3.2yrs

Average Tenure

55yo

Average Age

Experienced Management: IN's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Adams
President4.25yrsCA$1.10m0.59%
CA$ 151.4k
Steven Dinh
Member of Scientific Advisory Board1.5yrsno datano data
William Garner
Independent Chairman of the Boardno dataCA$74.15k0%
CA$ 0
Andrew Hull
Independent Director4yrsCA$49.15k0.36%
CA$ 92.4k
Adam Cutler
Independent Director4.83yrsCA$49.15k0%
CA$ 0
Catherine Sazdanoff
Independent Director1.17yrsno data0%
CA$ 0
Mauro Maccarrone
Member of Scientific Advisory Board2.92yrsno datano data
Vikramaditya Yadav
Member of Scientific Advisory Board2.33yrsno datano data

2.9yrs

Average Tenure

56.5yo

Average Age

Experienced Board: IN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

InMed Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InMed Pharmaceuticals Inc.
  • Ticker: IN
  • Exchange: TSX
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$25.477m
  • Shares outstanding: 5.22m
  • Website: https://www.inmedpharma.com

Number of Employees


Location

  • InMed Pharmaceuticals Inc.
  • 815 West Hastings Street
  • Suite 310
  • Vancouver
  • British Columbia
  • V6C 1B4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INTSX (The Toronto Stock Exchange)YesCommon SharesCACADAug 1999
MWGDB (Deutsche Boerse AG)YesCommon SharesDEEURAug 1999
IMLF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDAug 1999

Biography

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a se ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 05:47
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.